

28 February 2011 EMA/CVMP/37837/2011 Veterinary Medicines and Product Data Management

# Committee for Medicinal Products for Veterinary Use

Monthly report of application procedures, guidelines and related documents February 2011

The CVMP monthly report includes statistical data for the current and previous two years on scientific advice, initial evaluations, variations, line extensions, renewals, MRLs initial evaluations and MRLs extensions/modifications and arbitration and referral procedures.

In addition, the report includes a summary table of the opinions issued by the CVMP in the current year and a list of adopted guidelines and other public documents.

#### Applications for medicinal products for veterinary use and maximum residue limits (MRLs)

Scientific advice requests							
	95-08	2009	2010	2011	Total		
Submitted	69	11	21	2	103		
Advice given	65	8	18	2	93		

Initial evaluation								
	95-08 2009 2010 2011							
Full	110	14	16	2	142			
(Submitted)								
Abridged/	10	1	2	0	13			
generics								
(Submitted)								
Withdrawals	12	0	1	0	13			
Positive	91	13	14	4	122			
opinions								
Negative	1	0	0	0	1			
opinions								

Marketing authorisations							
95-08 2009 2010 2011 Total							
Granted	88	12	9	2	111		
Withdrawals	2	0	4	0	6		
Not renewed	2	0	0	0	2		

Extensions					
	95-08	2009	2010	2011	Total
Submitted	60	12	3	1	76
Withdrawals	2	1	1	0	4
Positive	40	7	8	0	55
opinions					
Negative	0	0	0	0	0
opinions					



Variations – applications submitted							
	95-08	2009	2010	2011	Total		
Type IA	339	32	76	12	571		
Type IB	339	41	63	7	3/1		
Type II	210	40	26	2	278		
Transfers	11	3	8	0	22		

Renewals							
	95-08	2009	2010	2011	Total		
Submitted	50	18	7	2	77		
Positive opinions	48	17	8	1	74		
Negative opinions	0	0	0	0	0		

Arbitrations and Community referrals								
	95-08 2009 2010 2011 Total							
Referrals	38	9	12	1	60			
submitted								
Opinions	20	15	11	0	46			
reached <sup>1</sup>		(5)	(1)		(6)			

<sup>&</sup>lt;sup>1</sup> Re-examination of opinions in brackets

Substances considered as not falling within the scope of Regulation (EC) No 470/2009					
	2011	Total			
Submitted	1	1			
Agreed	6	6			
Scientific advice recommended	0	0			

Establishment of MRLs for new substances								
	95-08 2009 2010 2011 Total							
Submitted	66	4	3	1	74			
Withdrawals	5	0	0	0	5			
Positive	54	2	2	1	59			
opinions <sup>2</sup>								
Negative	7	0	0	0	7			
opinions <sup>3</sup>								

Extensions / modifications/extrapolations of MRLs							
	95-08	2009	2010	2011	Total		
Submitted	98	2	10	1	111		
Withdrawals	4	0	0	0	4		
Positive	113	3	3	1	120		
opinions <sup>3</sup>							
Negative	6	0	0	0	6		
opinions <sup>4</sup>							
Extrapolations	50	0	0	0	50		

<sup>&</sup>lt;sup>2</sup> Including opinions recommending definitive MRLs for substances with previously provisional maximum residue limits

residue limits

<sup>3</sup> Including one opinion concluding that final MRL could not be established for a substance with provisional maximum residue limits previously established

### CVMP opinions in 2011 on medicinal products for veterinary use

Positive opinions

Pro	oduct	•	Marketing	The	erapeutic area	FM/	1A/CVMP	Fu	ropean Commission
1110			authorisation	•	Target species		Validation		·
•	Invented name		holder			•	Opinion	•	Opinion received  Date of decision
•	INN			•	Summary of indication		Active time		Notification
					maication		Clock stop		Official Journal
	CaniLeish	•	Virbac S.A.	•	Dogs		17/03/2010		13/01/2011
ľ	Carriceisii		VII Dac S.A.	•	Vaccine against	•	12/01/2011		13/01/2011
					Leishmania	•	210		
					infection	•	91		
•	ZULVAC 1 + 8	•	Pfizer Limited	•	Sheep	•	18/03/2010	•	13/01/2011
	Ovis		THZOI EITHICG	•	Vaccine for	•	12/01/2011		10/01/2011
					prevention of	•	180		
					viraemia caused	•	119		
					by Bluetongue				
					Virus serotypes 1				
					and 8				
•	BLUEVAC BTV8	•	CZ Veterinaria	•	Cattle, sheep	•	17/01/2009	•	10/02/2011
			S.A	•	Vaccine for	•	09/02/2011		
					active	•	180		
					immunisation	•	511		
					against				
					bluetongue				
					disease				
•	Procox	•	Bayer Animal	•	Dogs	•	16/02/2010	•	11/02/2011
•	Emodepside and		Health GmbH	•	Treatment of	•	09/02/2011		
	toltrazuril				dogs when mixed	•	210		
					parasitic	•	148		
					infections,				
					caused by				
					certain specific				
					roundworms and				
					coccidia are				
					suspected or				
					demonstrated				
•	Veraflox	•	Bayer Animal	•	Dogs, cats	•	19/05/2009	•	11/02/2011
•	Pradofloxacin		Health GmbH	•	Treatment for	•	14/07/2010		
					dogs and cats	•	205		
					with particular	•	217		
					infections caused	•	09/02/2011		
					by certain		e-consideration)		
					specific and		,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,		
					susceptible				
					pathogens				

### CVMP opinions in 2011 on establishment of MRLs for new substances

#### Positive opinions

<ul><li>Substance</li><li>INN</li></ul>	<ul><li>Therapeutic area</li><li>Target species</li></ul>	<ul><li>EMA/CVMP</li><li>Validation</li><li>Opinion</li><li>Active time</li><li>Clock stop</li></ul>	<ul><li>European Commission</li><li>Opinion received</li><li>Date of regulation</li><li>Official Journal</li></ul>
Methylpredni –     solone  (after provisional MRLs)	Bovine	<ul><li>n/a</li><li>12/01/2011</li><li>90</li><li>0</li></ul>	• 27/01/2011
Octenidine dihydrochloride	All mammalian food producing species	<ul><li>11/08/2009</li><li>08/02/2011</li><li>210</li><li>246</li></ul>	• 21/02/2011

## **Arbitrations and Community referrals in 2011**

Type of referral	Date of clock start	Product name
	CVMP opinion	• INN
Referral under Art. 34	• 11/11/2009	Fortekor vet and associated names
of Directive		- Danazanril hudrashlarida
2001/82/EC		Benazepril hydrochloride
Referral under Art. 34	• 14/04/2010	Synulox Lactating Cow and associated names
of Directive		Amoxicillin, clavulanic acid, prednisolone
2001/82/EC		• Amoxiciliiri, ciavulariic aciu, predriisolorie
Referral under Art.	• 14/07/2010	Combimox Lactating Cow
33(4) of Directive		Amoxicillin, clavulanic acid, prednisolone
2001/82/EC		74 Toxiciliti, clavalarile acia, preariisolorie
Referral under Art.	• 14/07/2010	Nisamox Lactating Cow
33(4) of Directive		Amaziaillin alayydania asid muadniaalana
2001/82/EC		Amoxicillin, clavulanic acid, prednisolone
Referral under Art.	• 14/07/2010	Combisyn Lactating Cow
33(4) of Directive		Amoxicillin, clavulanic acid, prednisolone
2001/82/EC		Amoxicillin, clavulanic acid, prednisolone
Referral under Art. 34	• 14/07/2010	Doxycycline 50% WSP and associated names
of Directive		Doxycycline hyclate
2001/82/EC		• Doxycycline Hyciate
Referral under Art. 34	• 14/07/2010	Doxyfar 50% WSP and associated names
of Directive		Doxycycline hyclate
2001/82/EC		• Doxycycline Hyciate
Referral under Art. 34	• 09/11/2010	Baytril 10% oral solution and associated
of Directive		names
2001/82/EC		Enrofloxacin
		LIIIOIIOXACIII

Type of referral	Date of clock start	Product name	
	CVMP opinion	• INN	
Referral under Art.	• 09/02/2011	Clavudale 50 mg tablet for cats and dogs	
33(4) of Directive			
2001/82/EC		Amoxicillin and clavulanic acid	

## Guidelines and working documents in 2011

#### **CVMP** Pharmacovigilance

Reference number	Document title	Status
EMA/CVMP/PhVWP/471721/2006	Recommendation on the basic surveillance of EudraVigilance Veterinary (EVVet) data	Adopted February 2011
EMA/CVMP/PhVWP/44873/2011	Public bulletin - Veterinary pharmacovigilance for 2010	Adopted February 2011

#### **CVMP Scientific Advisory Group on Antimicrobials**

Reference number	Document title	Status
EMA/CVMP/SAGAM/736964/2009	Reflection paper on meticillin- resistant <i>Staphylococcus</i> pseudintermedius (MRSP)	Adopted January 2011